Literature DB >> 20868305

Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy.

Daniel Xia1, Richard L Davis, Judith A Crawford, Jerrold L Abraham.   

Abstract

BACKGROUND: gadolinium (Gd)-containing MRI contrast agents (GdCA) are widely used in studies of brain tumors, and a number of reports suggest that under certain conditions, such as renal failure, Gd may be released from GdCA into patient's tissues. Whether this may happen in abnormal tissues in the absence of renal failure has not been studied.
PURPOSE: to test the hypothesis that the local retention of GdCA resulting from brain tumor-associated alterations in the blood-brain barrier (BBB) may result in the deposition of Gd released from the GdCA, depending on stability.
MATERIAL AND METHODS: in this retrospective study, 30 selected brain tumor biopsies from 28 patients (taken before and after an institutional switch from a less stable to an intermediate stable GdCA) were searched for Gd-containing deposits using scanning electron microscopy/energy dispersive X-ray spectroscopy (SEM/EDS). Relevant histories and laboratory results were obtained through institutional electronic records. Associations between the presence of deposits and other variables were tested for statistical significance using the two-tailed Fisher's exact test.
RESULTS: insoluble deposits containing Gd associated with phosphorus and calcium were found in seven biopsies from five patients. These deposits were found in patients with estimated GFRs above 53 ml/min, and were detected more often in those receiving GdCA before the switch from a less stable to an intermediate stable GdCA (P = 0.04), and may be more frequent in patients receiving more than one contrast-enhanced MR scan (P = 0.15).
CONCLUSION: Gd-containing deposits are present in brain tumors following contrast-enhanced MR scans in patients without severe renal disease. Further studies are needed to assess the clinical importance of the deposits we observed and to determine whether they are also found in other conditions that alter the integrity of the BBB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868305     DOI: 10.3109/02841851.2010.515614

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  21 in total

Review 1.  Safety issues related to intravenous contrast agent use in magnetic resonance imaging.

Authors:  Skorn Ponrartana; Michael M Moore; Sherwin S Chan; Teresa Victoria; Jonathan R Dillman; Govind B Chavhan
Journal:  Pediatr Radiol       Date:  2021-04-19

2.  Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.

Authors:  A Luana Stanescu; Dennis W Shaw; Nozomu Murata; Kiyoko Murata; Joe C Rutledge; Ezekiel Maloney; Kenneth R Maravilla
Journal:  Pediatr Radiol       Date:  2020-01-27

3.  Changes in Signal Intensity of the Dentate Nucleus and Globus Pallidus in Pediatric Patients: Impact of Brain Irradiation and Presence of Primary Brain Tumors Independent of Linear Gadolinium-based Contrast Agent Administration.

Authors:  Benita Tamrazi; Binh Nguyen; Chia-Shang J Liu; Colleen G Azen; Mary B Nelson; Girish Dhall; Marvin D Nelson
Journal:  Radiology       Date:  2017-11-30       Impact factor: 11.105

Review 4.  Gadolinium retention in the body: what we know and what we can do.

Authors:  Enrico Tedeschi; Ferdinando Caranci; Flavio Giordano; Valentina Angelini; Sirio Cocozza; Arturo Brunetti
Journal:  Radiol Med       Date:  2017-03-30       Impact factor: 3.469

Review 5.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

6.  Gadolinium retention in gliomas and adjacent normal brain tissue: association with tumor contrast enhancement and linear/macrocyclic agents.

Authors:  Aida Kiviniemi; Maria Gardberg; Paul Ek; Janek Frantzén; Johan Bobacka; Heikki Minn
Journal:  Neuroradiology       Date:  2019-02-02       Impact factor: 2.804

7.  Diagnostic accuracy of non-contrast magnetic resonance enterography in detecting active bowel inflammation in pediatric patients with diagnosed or suspected inflammatory bowel disease to determine necessity of gadolinium-based contrast agents.

Authors:  Stacy J Kim; Thomas L Ratchford; Paula M Buchanan; Dhiren R Patel; Ting Y Tao; Jeffrey H Teckman; Jeffrey J Brown; Shannon G Farmakis
Journal:  Pediatr Radiol       Date:  2019-03-21

Review 8.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

Review 9.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

Review 10.  T1 hyperintensity on brain imaging subsequent to gadolinium-based contrast agent administration: what do we know about intracranial gadolinium deposition?

Authors:  Nigel Hoggard; Giles H Roditi
Journal:  Br J Radiol       Date:  2016-10-19       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.